Public health discussions surrounding problematic drug use often focus on overdose prevention, infectious diseases, mental health, and access to treatment services. Yet one of the most significant contributors to illness and premature mortality among people who use drugs frequently receives far less attention: smoking.
A recent briefing paper from the Global State of Tobacco Harm Reduction (GSTHR) highlights an important but often overlooked reality. Smoking prevalence among people experiencing problems with drug use is substantially higher than in the general population across many countries, and tobacco-related disease represents a major source of preventable illness and death within this population.
This raises an important question for public health policymakers: are health systems overlooking one of the largest and most preventable health risks affecting people who use drugs?
Smoking and Health Inequalities
The relationship between smoking and social disadvantage has long been recognised. Smoking prevalence is often higher among populations facing poverty, mental health challenges, housing instability, and substance use disorders.
People experiencing problems with drug use frequently face multiple and overlapping health vulnerabilities. In many cases, smoking rates remain extremely high, and tobacco-related diseases such as cardiovascular disease, chronic respiratory illness, and cancer contribute substantially to morbidity and premature mortality.
Yet smoking is often treated as a secondary issue.
Treatment services understandably prioritise immediate risks such as overdose, acute withdrawal, blood-borne infections, and stabilisation. However, focusing exclusively on these immediate threats can unintentionally obscure the significant long-term health burden associated with smoking.
For some individuals, tobacco-related disease may ultimately represent one of the greatest threats to long-term health outcomes.
The Missing Conversation in Harm Reduction
Harm reduction has become an established public health principle in many areas of drug policy.
Needle and syringe programmes, opioid substitution therapies, overdose prevention initiatives, and naloxone distribution programmes are all grounded in a pragmatic recognition that reducing risk can save lives, even when abstinence is not immediately achievable.
Yet tobacco harm reduction often occupies a less prominent place within these discussions.
This inconsistency raises important questions.
If reducing risk is accepted as an appropriate objective for addressing other forms of substance use, should similar principles also apply to smoking among adults who face problems with drug use?
This does not imply that smoking cessation should be abandoned as a public health goal. On the contrary, smoking cessation remains the ideal outcome. However, evidence from many areas of addiction treatment suggests that not all smokers are immediately willing or able to quit nicotine altogether.
For these individuals, strategies that reduce exposure to the toxicants generated by smoking may warrant consideration within broader discussions about improving health outcomes.
Smoking Versus Nicotine
One reason these conversations can become difficult is that nicotine and smoking are often discussed as though they are the same issue.
They are not.
The overwhelming burden of smoking-related disease is caused primarily by combustion. Burning tobacco generates thousands of chemicals, including numerous toxicants and carcinogens directly associated with cancer, respiratory disease, and cardiovascular illness.
Nicotine is addictive and is not risk-free. However, it is not the primary cause of the diseases responsible for most smoking-related deaths.
This distinction matters because reducing exposure to smoke may represent an important public health objective in populations where smoking prevalence remains disproportionately high.
Why Vulnerable Populations Matter
People experiencing problems with drug use often face complex social and health challenges simultaneously.
Many experience significant barriers to healthcare access, poorer health outcomes, social exclusion, and reduced life expectancy. High smoking prevalence can compound these existing inequalities and contribute to additional disease burdens over time.
This means that tobacco-related harm should not be viewed as a separate issue from broader health inequalities. Rather, it forms part of a wider pattern of vulnerability and preventable illness.
Addressing smoking within this population therefore has implications that extend beyond tobacco control alone. It is also a question of health equity.
Reducing smoking prevalence among highly disadvantaged populations may represent an opportunity to reduce preventable disease and improve long-term health outcomes among individuals who often experience some of the greatest health inequalities in society.
A Role for Tobacco Harm Reduction?
The question is not whether people who use drugs should be encouraged to use nicotine products.
They should not.
The question is whether adults who already smoke and face problems with drug use should have access to a full range of evidence-based smoking cessation interventions and appropriately regulated lower-risk alternatives if they are unable or unwilling to stop using nicotine entirely.
This distinction is critical.
The potential public health value of smoke-free nicotine products arises when they help adults who smoke move away from combustible tobacco. That potential benefit disappears if products are used by young people, non-smokers, or individuals who would not otherwise use nicotine.
Any harm reduction approach must therefore be accompanied by robust safeguards, including youth protections, responsible marketing practices, product standards, and continued monitoring of population-level outcomes.
Looking Ahead
The GSTHR briefing serves as an important reminder that smoking remains one of the largest preventable causes of disease and death among people experiencing problems with drug use.
The challenge for policymakers is not whether immediate harms such as overdose and infectious diseases deserve attention. They unquestionably do.
The challenge is ensuring that smoking-related disease does not remain an overlooked contributor to poor health outcomes among one of the world’s most vulnerable populations.
Harm reduction has long recognised that reducing risk can save lives, even when abstinence is not immediately achievable. The question for tobacco control and public health systems is whether this principle should be applied consistently to smoking among adults who face problems with drug use.
Ignoring tobacco-related harm may represent a missed opportunity to improve health outcomes, reduce health inequalities, and address one of the most persistent and preventable sources of disease among vulnerable populations.
For public health systems committed to reducing preventable illness and improving health equity, tobacco harm reduction may be a conversation that can no longer remain at the margins of addiction policy.
Source
